You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Targeting the Fcμ-receptor in chronic lymphocytic leukemia with a novel IgM-derived antibody-drug conjugate
  1. Martin Skarzynski1,
  2. Bérengère Vire1,
  3. Joshua D Thomas2,
  4. Christopher G Nelson2,
  5. Alexandre David3,
  6. Georg Aue1,
  7. Terrence R Burke2,
  8. Christoph Rader4,5 and
  9. Adrian Wiestner1
  1. Aff1 grid.279885.90000000122934638Hematology BranchNational Heart, Lung, and Blood Institute Bethesda MD USA
  2. Aff2 grid.48336.3a0000000419368075Chemical Biology Laboratory, Molecular Discovery Program, Frederick National Laboratory for Cancer ResearchCenter for Cancer Research, National Cancer Institute Frederick MD USA
  3. Aff3 grid.419681.30000000121649667Laboratory of Viral DiseasesNational Institute of Allergy and Infectious Diseases Bethesda MD USA
  4. Aff4 grid.417768.b0000000404839129Experimental Transplantation and Immunology BranchCenter for Cancer Research, National Cancer Institute Bethesda MD USA
  5. Aff5 grid.214007.00000000122199231Department of Cancer Biology and Department of Molecular TherapeuticsThe Scripps Research Institute, Scripps Florida Jupiter FL USA

https://doi.org/10.1186/2051-1426-1-S1-P136

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Fc-receptors (FcR) are widely expressed on cells of the immune system. FcμR is a transmembrane protein with an extracellular Ig-like domain homologous to the FcR for both IgA and IgM (Fcα/μR) and the polymeric Ig receptor (pIgR). FcμR is expressed on CD19+B cells, CD4+/CD8+ T cells, and CD56+/CD3- NK cells. In addition, several groups have reported that FcμR is overexpressed in chronic lymphocytic leukemia (CLL) cells. Using immunofluorescence staining, we found that FcμR can rapidly uptake IgM, internalize it in specific vesicles and transport it through the endocytic pathway to the lysosomal compartment. Interestingly, aggregation of FcμR with IgM leads to rapid internalization of IgM (>80% internalized within 5 minutes) whereas mAb bound FcμR is not internalized. Overexpression on CLL cells and rapid internalization of FcμR represents a potential means of selectively delivering a cytotoxic agent into malignant cells. To this end, we engineered a protein scaffold derived from the CH2-CH3-CH4 IgM constant regions with a C-terminal selenocysteine that allows covalent conjugation of drugs or toxins to the protein scaffold. We verified that the scaffold also binds FcμR, is rapidly internalized and has a serum circulatory half-life comparable to IgM (~18hrs) in NOD/SCID/IL-2Rγnull (NSG) mice. We then demonstrated that the scaffold, when conjugated to a cytotoxic small molecule, kills malignant B cells, but not normal T cells, from CLL patients in vitro and in NSG mice. These findings indicate that the rapid internalization of IgM-FcμR complexes can be exploited for therapeutic purposes. Taken together, IgM-derived protein scaffold antibody-drug conjugates appear as promising treatment modalities for CLL and possibly other malignancies.